Belgium-based UCB has opened its new £25 million biologics Research and Development centre in Slough, UK. The company, headquartered in Brussels, said the centre will be used for research into therapeutic antibodies. UCB will employ 100 scientists, in addition to the staff already employed at the site.
The new UCB New Medicines Centre for Collaborative Research will also be located within the biologics centre.
UCB claims to be the fourth largest investor in UK pharmaceutical Research and Development, investing over £200 million in 2008.
Further reading - An in-depth analysis of the UK pharmaceutical market, including some background information on drug companies and Research and Development, is available from Espicom: The Pharmaceutical Market: United Kingdom (published March 2009)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment